Abstracts tagged "safety and growth factors"

Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, Eric Vignon ⁵, David Walsh ⁶, Alexander White ⁷, Satoru Nakajo ⁸, Robert Fountaine ⁹, Anne Hickman ⁹, Glenn Pixton ¹⁰, Lars Viktrup ¹¹, Mark T. Brown ⁹, Christine R. West ⁹ and Kenneth M. Verburg ⁹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Université Claude Bernard Lyon 1, Lyon, France, ⁶Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁷Progressive Medical Research, Port Orange, FL, ⁸Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Morrisville, NC, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
Abstract Number: 2756 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, David Walsh ⁵, Alexander White ⁶, Satoru Nakajo ⁷, Robert Fountaine ⁸, Anne Hickman ⁸, Glenn Pixton ⁹, Lars Viktrup ¹⁰, Mark T. Brown ⁸, Christine R. West ⁸ and Kenneth M. Verburg ⁸, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁶Progressive Medical Research, Port Orange, FL, ⁷Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Morrisville, NC, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab, a monoclonal antibody inhibiting nerve growth factor (NGF), is under investigation for the treatment of chronic pain conditions. In prior osteoarthritis (OA) studies,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].